Dulaglutide (Trulicity) consistently ranks as the GLP-1 medication with the lowest rates of nausea, vomiting, and diarrhea in clinical trial data. In a Bayesian network meta-analysis published in Frontiers in Pharmacology, dulaglutide had the lowest risk of inducing nausea and vomiting among all GLP-1 drugs studied, while tirzepatide (Mounjaro/Zepbound) carried the highest risk. That said, the differences between medications are more nuanced than a simple ranking suggests, and how you start and increase your dose matters just as much as which drug you choose.
How GLP-1 Medications Rank for GI Side Effects
A large network meta-analysis compared gastrointestinal side effects across seven GLP-1 medications using data from clinical trials in people with type 2 diabetes. The results ranked each drug from lowest to highest risk for six common side effects: nausea, diarrhea, vomiting, indigestion, constipation, and appetite loss.
Dulaglutide landed at or near the bottom of the risk rankings for nearly every category. It ranked lowest for both nausea and vomiting, and middle-of-the-pack for diarrhea and constipation. Exenatide (Byetta/Bydureon) also showed relatively good tolerability across multiple categories.
Semaglutide (Ozempic/Wegovy) ranked second highest for nausea, third for vomiting, and highest for constipation. Tirzepatide ranked highest overall for gastrointestinal side effects, topping the list for nausea, diarrhea, indigestion, and appetite loss. This is notable because tirzepatide is a dual-action drug that targets both GLP-1 and GIP receptors, and early preclinical work had suggested the GIP component might buffer some GI distress. In practice, the side effect profile remains comparable to or worse than pure GLP-1 drugs, likely because tirzepatide is typically prescribed at potent doses for weight loss.
Real-World Data Tells a Slightly Different Story
Clinical trials enroll carefully selected patients and follow strict dosing schedules, so real-world data can shift the picture. A cross-sectional analysis of the NIH All of Us cohort, which tracks health outcomes in a diverse group of Americans, compared side effects across GLP-1 drugs using semaglutide as the reference point. In that dataset, dulaglutide and liraglutide both had significantly higher odds of abdominal pain and nausea/vomiting compared to semaglutide. Dulaglutide, liraglutide, and exenatide all had significantly higher odds of gastroparesis (severely delayed stomach emptying) compared to semaglutide, with exenatide showing the highest gastroparesis rate at 6.9%.
This seems to contradict the clinical trial rankings, where dulaglutide looked better than semaglutide. The likely explanation is dose. Semaglutide for diabetes is typically used at 0.5 to 1 mg weekly, while the weight loss dose is 2.4 mg. Clinical trial rankings reflect the diabetes dosing range. In the real world, where many patients are on higher weight-loss doses of semaglutide, the GI burden climbs. Meanwhile, dulaglutide is only approved for diabetes at a maximum of 4.5 mg, so real-world users may be on comparatively milder regimens. The takeaway: which drug causes fewer side effects depends partly on what dose you need.
Serious Side Effects Beyond Nausea
Most GLP-1 side effects are uncomfortable but not dangerous. About 6.5% of people using any GLP-1 medication discontinue it due to adverse events, compared to 3.6% on placebo. Nausea is the leading reason people quit, followed by vomiting and diarrhea.
Rarer but more serious complications include pancreatitis, gallbladder disease, and gastroparesis. A JAMA study examining GLP-1 drugs prescribed for weight loss found that semaglutide was associated with 4.6 cases of pancreatitis per 1,000 person-years, compared to 7.9 for liraglutide. For gallbladder disease, semaglutide had 11.7 cases per 1,000 person-years versus 18.6 for liraglutide. Gastroparesis rates were 9.1 per 1,000 person-years for semaglutide and 7.3 for liraglutide. These are low numbers overall, but liraglutide (Saxenda/Victoza) tends to carry slightly higher rates of pancreatitis and biliary problems, while semaglutide edges higher for gastroparesis.
Oral vs. Injectable Semaglutide
If you’re considering semaglutide specifically, the delivery method matters. Oral semaglutide (Rybelsus) tends to cause more GI distress than the injectable version (Ozempic). User-reported data shows nausea rates of about 41% for the oral pill compared to 33% for the injection. Diarrhea follows a similar pattern: roughly 21% for oral versus 16% for injectable. The pill must be taken on an empty stomach with minimal water to ensure absorption, and this direct contact with the GI tract likely contributes to the higher nausea rates.
How Dose Titration Affects Tolerability
Regardless of which GLP-1 you take, the speed at which you increase your dose is one of the strongest predictors of how sick you’ll feel. A randomized study comparing standard versus gradual, flexible semaglutide titration found that slower dose escalation cut nausea rates from 64% to 45%. The duration of nausea symptoms also dropped sharply, from an average of 6.3 days to 2.9 days. Most striking was the difference in discontinuation: 19% of patients on standard titration quit because of GI side effects, compared to just 2% on the flexible schedule. Most of those who stopped were able to restart successfully with a slower approach.
This means that even a drug with a higher GI risk ranking, like semaglutide or tirzepatide, can become much more tolerable if you and your prescriber take a patient approach to dose increases. Jumping to a higher dose before your body adjusts is the single most common reason people have a rough experience.
Women May Experience More Side Effects
Sex plays a measurable role in GLP-1 tolerability. Women are roughly twice as likely as men to discontinue GLP-1 treatment due to gastrointestinal side effects. In a liraglutide trial, 28% more women than men reported adverse effects. In a dulaglutide trial, that gap widened to 41%. Part of the explanation is pharmacokinetic: women show about 32% higher drug exposure than men at the same body weight when taking liraglutide. But even when drug exposure levels are similar, women report more side effects from semaglutide than men, suggesting hormonal or receptor-level differences in how women’s bodies respond to GLP-1 signaling.
If you’re a woman who has struggled with GI side effects on one GLP-1 drug, this pattern is worth knowing. It doesn’t mean these medications won’t work for you, but it does mean slower titration and possibly choosing a better-tolerated agent like dulaglutide could make a meaningful difference in your experience.
Picking the Right GLP-1 for You
If minimizing side effects is your top priority and you’re using a GLP-1 for type 2 diabetes, dulaglutide has the strongest evidence for tolerability at standard doses. It ranks lowest for nausea and vomiting in clinical trials and, while real-world data is messier, it remains a reasonable first choice for people concerned about GI problems.
If weight loss is the primary goal, the picture gets more complicated. Semaglutide and tirzepatide produce significantly more weight loss than dulaglutide, but at higher doses they also cause more GI distress. The tradeoff is real, but manageable. Slow titration can reduce nausea by roughly 30% and cut treatment discontinuation dramatically. For many people, the right answer isn’t necessarily the drug with the lowest side-effect ranking on paper. It’s the drug that matches their treatment goals, started at the lowest dose, and increased only as fast as their body allows.